Idiopathic Pulmonary Fibrosis Market Report Examines Leading Companies And Growth Opportunities

The idiopathic pulmonary fibrosis (IPF) market is poised for notable expansion over the coming years, driven by advancements in treatment options and increased awareness of this rare lung disease. As research intensifies and therapeutic strategies evolve, the market is set to witness substantial growth through 2030. Below, we explore the market size, key players, emerging trends, and detailed segmentation shaping the future of IPF treatment.

Strong Growth Outlook for the Idiopathic Pulmonary Fibrosis Market Size Through 2030
The idiopathic pulmonary fibrosis market is forecasted to reach $6.16 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2%. This expansion is largely fueled by heightened investments in pulmonary fibrosis research and the development of next-generation antifibrotic medications. Additionally, the increasing incorporation of real-world evidence to guide treatment choices, the growth of online and specialty pharmacy distribution channels, and rising awareness about rare respiratory disorders are all playing major roles in market growth. Key trends anticipated during this period include broader acceptance of antifibrotic therapies, greater emphasis on early and precise diagnoses, increasing use of combination drug regimens, growth in home-based and long-term condition management, and more patient participation in clinical trials for innovative treatments.

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.37 billion in 2025 to $4.66 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to limited treatment options for fibrotic lung diseases, rising prevalence of aging population, improved clinical recognition of IPF, approval of nintedanib and pirfenidone, increased hospital-based management of chronic lung disorders.

Download a free sample of the idiopathic pulmonary fibrosis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Driving the Idiopathic Pulmonary Fibrosis Market
The IPF market is dominated by several prominent pharmaceutical and biotech companies, such as F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, and Galecto Inc.

In a notable industry development, October 2023 saw US biopharma company Aileron Therapeutics acquire Lung Therapeutics Inc. for an undisclosed sum. This acquisition strengthens Aileron's pipeline by adding Lung Therapeutics' clinical-stage IPF asset, LTI-03, accelerating their efforts in idiopathic pulmonary fibrosis. Lung Therapeutics specializes in developing novel peptide-based treatments such as LTI-03, a Caveolin-1-related peptide targeting orphan fibrotic lung diseases including IPF.

View the full idiopathic pulmonary fibrosis market report:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends and Innovations in the Idiopathic Pulmonary Fibrosis Market
The industry is increasingly focused on developing innovative therapies like anti-fibrotic small-molecule inhibitors to maintain competitive advantage. These inhibitors are designed to directly target and suppress fibrotic activity within the body, offering new hope for patients.

For example, in June 2023, Insilico Medicine, a US clinical-stage biotech firm using generative artificial intelligence (AI), announced the start of Phase II clinical trials for INS018_055. This drug is the world's first anti-fibrotic small molecule inhibitor developed through AI technology. The trial is a randomized, double-blind, placebo-controlled study assessing safety, tolerability, pharmacokinetics, and early efficacy of a 12-week oral dosing regimen in IPF patients. This breakthrough highlights the growing role of AI in drug discovery and represents a promising advancement in IPF treatment.

Detailed Segmentation of the Global Idiopathic Pulmonary Fibrosis Market
This report segments the idiopathic pulmonary fibrosis market based on multiple factors as follows:

1) By Drug Type:
- Nintedanib
- Pirfenidone
- Other Drug Types

2) By Mode of Action:
- Antifibrotic Agents
- Tyrosine Kinase Inhibitors
- Other Modes of Action

3) By Route of Administration:
- Oral
- Parenteral

4) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Providers

5) By End Users:
- Hospitals and Clinics
- Other End Users

Additional subcategories provide further granularity, such as indications, dosage forms, and administration routes for Nintedanib and Pirfenidone, as well as classifications of other drug types including emerging therapies and combination treatments. This comprehensive segmentation offers a detailed understanding of the IPF market landscape and its evolving dynamics.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.